Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.5452W HIGH $7.18
Volume
420.08 K
Value Traded
10.56 M
Short % Float
19.93%
-2.51%Week
-6.52%1 Month
-29.57%3 Month
-30.17%6 Month
-75.93%5 Year
-69.48%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
774.43 M
EPS (TTM)
-1.07
P/E Ratio
-
Ent. Value
573.72 M
Total Shares
189.63 M
Float Shares
164.93 M
Insiders
13.00%
Institutions
89.37%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ANNX Catalyst Timeline
Dated clinical, regulatory and corporate events for Annexon, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Annexon, Inc.
332Total events
12Upcoming
72Tier-1 (high impact)
2020 to 2026Coverage
Upcoming catalysts 2
Event history 50
◆Oral PresentationVonaprument (ANX007)Presentation
Oral presentation of post hoc analysis of vision outcomes in eyes with subfoveal RPE lesions from Phase 2 ARCHER trial at Retina Society 59th Annual Scientific Meeting
Geographic Atrophysource ↗
●Protocol AmendmentVonaprument (ANX007)Trial
Addition of Month 24 dual primary endpoint to Phase 3 program
geographic atrophysource ↗
●Trial InitiationVonaprument (ANX007)Trial
Launch of open-label extension study
geographic atrophysource ↗
▲Topline ReadoutTanruprubartFiledClinical Data
Initial cohort data from FORWARD study showed rapid clinical responses in all treated patients
Guillain-Barré syndromesource ↗
●EU MAA SubmissionTanruprubartFiledEx-US Regulatory
MAA currently under review by EMA
Guillain-Barré syndromesource ↗
▲Debt Royalty FinancingCorporate
Annexon entered into a strategic credit facility agreement with Oxford Finance for up to $200 million
◆Oral PresentationVonaprument (ANX007)Presentation
Oral presentation on baseline characteristics associated with BCVA 15-letter loss in GA patients from Phase 2 ARCHER study at ASRS 2026
geographic atrophysource ↗
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
◆Oral PresentationPresentation
Annexon to present at Bank of America Securities Health Care Conference 2026
◆Oral PresentationPresentation
Annexon to present at 25th Annual Needham Virtual Healthcare Conference
◆Topline ReadoutVonaprument (ANX007)Clinical Data
Pivotal Phase 3 topline data for vonaprument in GA
Dry AMD with Geographic Atrophy (GA)source ↗
◆Topline ReadoutVonaprument (ANX007)Clinical Data
ARCHER II topline data expected
geographic atrophysource ↗
●EU MAA SubmissionTanruprubartFiledEx-US Regulatory
MAA filed with EMA for tanruprubart in GBS
Guillain-Barré syndrome (GBS)source ↗
◆Oral PresentationVonaprument (ANX007)Presentation
KOL event to discuss vonaprument for GA
geographic atrophysource ↗
◆Oral PresentationPresentation
Annexon to present at TD Cowen 46th Annual Health Care Conference
●EU MAA SubmissionTanruprubartFiledEx-US Regulatory
MAA filed for tanruprubart in Europe
Guillain-Barré Syndrome (GBS)source ↗
◆EU MAA SubmissionTanruprubartFiledEx-US Regulatory
MAA submission for tanruprubart in GBS
Guillain-Barré Syndrome (GBS)source ↗
◆Enrollment CompleteVonaprument (ANX007)Trial
Enrollment completion of Phase 3 ARCHER II trial for ANX007 in GA expected in 2H 2025
geographic atrophysource ↗
▼Equity OfferingCorporate
Closing of public offering and full exercise of underwriters' option for gross proceeds of $86.25 million
▼Equity OfferingCorporate
Annexon announces proposed public offering of $75 million common stock and pre-funded warrants
▲Enrollment CompleteVonaprument (ANX007)Trial
Accelerated completion of enrollment for ARCHER II (659 patients)
Dry AMD with Geographic Atrophy (GA)source ↗
▲EMA PrimeVonaprument (ANX007)Ex-US Regulatory
Selected for EMA PRIME Product Development Candidate Pilot
Dry AMD with Geographic Atrophy (GA)source ↗
▲EMA PrimeVonaprument (ANX007)Ex-US Regulatory
EMA selects vonaprument for Product Development Coordinator pilot
dry age-related macular degeneration with geographic atrophysource ↗
◆Oral PresentationVonaprument (ANX007)Presentation
Oral presentation on ARCHER II trial design and rationale at ASRS annual meeting
dry age-related macular degeneration with geographic atrophysource ↗
▲Enrollment CompleteVonaprument (ANX007)Trial
Enrollment completed in Phase 3 ARCHER II trial of vonaprument for dry AMD with GA
dry age-related macular degeneration with geographic atrophysource ↗
◆Enrollment CompleteVonaprument (ANX007)Trial
Enrollment completion expected in Q3 2025
dry age-related macular degeneration with geographic atrophysource ↗
▲Enrollment CompleteVonaprument (ANX007)Trial
Enrollment completed in Phase 3 ARCHER II trial
geographic atrophysource ↗
◆Timing GuidanceANX005FiledPresentation
BLA submission for ANX005 in GBS expected in 1H 2025
Guillain-Barré syndromesource ↗
◆Trial CompletionANX1502Trial
Proof-of-concept trial completion for ANX1502 anticipated mid-2025
Cold Agglutinin Disease (CAD)source ↗
◆Full ResultsANX1502Clinical Data
ANX1502 POC dataset in up to seven CAD patients
Cold Agglutinin Disease (CAD)source ↗
●BLA SubmissionANX005FiledRegulatory Filing
BLA submission for ANX005
Guillain-Barré syndrome (GBS)source ↗
◆Oral PresentationTanruprubartFiledPresentation
Real-World Evidence study oral presentation at PNS Annual Meeting
Guillain-Barré Syndrome (GBS)source ↗
●Oral PresentationVonaprument (ANX007)Presentation
Oral presentation on visual function outcomes in Phase 2 ARCHER trial at Retina World Congress
Dry AMD with GAsource ↗
●Poster PresentationVonaprument (ANX007)Presentation
Poster presentation on microglia-induced neuronal injury attenuation with C1q inhibition in GA and HD at ARVO 2025
Geographic Atrophy (GA) and Huntington's Disease (HD)source ↗
◆Poster PresentationTanruprubartFiledPresentation
Poster presentations at PNS Annual Meeting reinforcing early and durable benefits of tanruprubart
Guillain-Barré Syndrome (GBS)source ↗
◆Oral PresentationANX005FiledPresentation
Phase 3 data oral presentation at AAN 2025
Guillain-Barré Syndrome (GBS)source ↗
◆Type B MeetingTanruprubartFiledFDA Meeting
FDA meeting for tanruprubart scheduled for Q2 2025 ahead of planned BLA submission
Guillain-Barré Syndrome (GBS)source ↗
▲Trial InitiationTanruprubartFiledTrial
Initiation of open-label tanruprubart FORWARD study expected in Q2 2025
Guillain-Barré Syndrome (GBS)source ↗
Past FDA Catalysts and PDUFA Decisions
How ANNX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-25 | vonaprument (formerly ANX007) | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D39 / 100
Pipeline Score
$83M
Pipeline Value
Richly Valued
Valuation Signal
6
Drugs Scored
0.1x
rNPV / MCap
Top 40%
Micro Cap(rank 264 of 658)
Percentile Rank
Annexon, Inc. faces pipeline headwinds (39/100), with $347M risk-adjusted pipeline value, led by ANX105 in Healthy (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ANX105 Monoclonal antibodyCompletedNCT05288881 | Healthy | Phase 1 | COMPLETED | 23 | Jun 19, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every ANNX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| vonaprument Fast Track | geographic atrophy associated with dry AMD | Phase 2 | 2026-07-14 | statistically significant, time and dose-dependent protection from vision lossRead More | Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Love DouglasDirector, Officer (PRESIDENT AND CEO) | Buy | 26,065 390,476 held | $3.83 | 09/24/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ANNX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Redmile Group, LLC | 4.6 % (-13.2 %) | 67.78 M | 11.87 M | -18.42% ( -2.68 M) |
ANNX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ANNX ranks across every disease it competes in
Competitive Position is a premium feature
See how ANNX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialANNX News
ANNXAnnexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
Annexon, Inc. announced two oral presentations regarding vonaprument at The Retina Society's 59th Annual Scientific Meeting. The presentations will focus on patient baseline characteristics from the ongoing Phase 3 ARCHER II trial, which aims to demonstrate vision protection in geographic atrophy. Results from this pivotal trial are expected in the fourth quarter of 2026.
Read more →ANNX▲ +6.1%on this news
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. has granted inducement equity awards to two new non-executive employees under its 2022 Employment Inducement Award Plan. The awards, totaling options for 275,500 shares, were approved on September 12, 2026, and are part of the company's strategy to enhance its workforce. The options have a ten-year term and will vest over four years.
Read more →ANNXAnnexon to Participate in Upcoming September Investor Conferences
Annexon, Inc. announced that its CEO, Douglas Love, will participate in several investor conferences in September 2026. These events include the Wells Fargo 21st Annual Healthcare Conference, the Cantor Global Healthcare Conference, and the H.C. Wainwright 28th Annual Global Investment Conference. Live webcasts of the presentations will be accessible on their website.
Read more →ANNXAnnexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Annexon has reported positive clinical outcomes from the GBS FORWARD study, reinforcing the effectiveness of Tanruprubart. The treatment's consistency and reproducibility were highlighted, with a Biologics License Application (BLA) submission anticipated in Q4 2026. Additionally, the Phase 3 GA program for Vonaprument has been expanded, focusing on dual primary endpoints at months 15 and 24.
Read more →ANNXAnnexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
Annexon, Inc. has expanded its Phase 3 program for vonaprument in geographic atrophy by adding a Month 24 dual primary endpoint, complementing the existing Month 15 primary endpoint. This expansion aims to strengthen the study's design and efficacy evaluation. Additionally, an open-label extension study has been launched to gather further long-term data on the treatment's effects.
Read more →ANNXAnnexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors
Annexon, Inc. has appointed Dr. Mark S. Blumenkranz to its Board of Directors. With over 40 years of experience in clinical, scientific, and corporate leadership, Dr. Blumenkranz is expected to drive innovation in the field of retinal disease. This strategic move aims to strengthen Annexon's position in advancing targeted immunotherapies.
Read more →ANNXAnnexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
Annexon, Inc. reported promising early results from the FORWARD study, where all ten patients treated with tanruprubart for Guillain-Barré syndrome (GBS) showed rapid improvement in muscle strength within days. This investigational therapy aims to address the significant unmet need for GBS treatments and is under review by the EMA, with a BLA submission planned for Q4 2026.
Read more →ANNXAnnexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
Annexon, Inc. has announced a strategic credit facility agreement with Oxford Finance for up to $200 million. This funding aims to support the potential global commercialization of its therapies, vonaprument and tanruprubart, which target neuroinflammatory diseases. The initial draw of $50 million has been secured, with additional funds contingent on achieving specific milestones.
Read more →ANNX▲ +17.1%on this news
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026
Annexon, Inc. announced an oral presentation at the ASRS 2026 meeting, highlighting findings from the Phase 2 ARCHER trial of vonaprument. The trial demonstrated significant vision preservation in patients with geographic atrophy associated with dry AMD. The presentation will emphasize baseline factors linked to visual acuity loss, aiding patient selection for the ongoing Phase 3 ARCHER II trial, with topline data expected in late 2026.
Read more →ANNXAnnexon to Participate in Upcoming June Investor Conferences
Annexon, Inc. announced its participation in two upcoming investor conferences in June 2026. Douglas Love, the CEO, will engage in fireside chats at the Jefferies Global Healthcare Conference and the Goldman Sachs Annual Global Healthcare Conference. The presentations will be accessible via live webcasts and archived for later viewing.
Read more →ANNXAnnexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones
Annexon, Inc. reported its first quarter 2026 financial results and highlighted key milestones in its portfolio. The company anticipates pivotal Phase 3 data for vonaprument for Geographic Atrophy in Q4 2026 and is awaiting EU approval for tanruprubart as a therapy for Guillain-Barré Syndrome. Additionally, proof-of-concept data for ANX1502 is expected in 2026, supported by a strong financial position.
Read more →ANNXAnnexon to Present at the Bank of America Securities Health Care Conference 2026
Annexon, Inc. will present at the Bank of America Securities Health Care Conference on May 13, 2026. Douglas Love, the CEO, will discuss the company's advancements in targeted immunotherapies for neuroinflammatory diseases. A live webcast will be available, and a replay will be archived for 30 days. This presentation aims to showcase Annexon's innovative approach to treating serious conditions affecting millions.
Read more →ANNXAnnexon to Present at the 25th Annual Needham Virtual Healthcare Conference
Annexon, Inc. will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. Douglas Love, the CEO, will discuss the company's advancements in targeted immunotherapies for neuroinflammatory diseases. The event will be accessible via a live webcast, with a replay available for 30 days post-presentation.
Read more →ANNXAnnexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA
Annexon announced its fourth quarter and year-end 2025 financial results, detailing significant progress in its drug pipeline, including the expected ARCHER II Phase 3 data for vonaprument in Q4 2026. The company filed for Marketing Authorization for tanruprubart in Europe, aiming to be a leading therapy for Guillain-Barr syndrome. Despite financial losses amounting to $48.3 million in Q4 2025, Annexon reported a strong cash position of approximately $238 million, which will facilitate its operations into mid-2027 as it advances its pivotal clinical programs.
Read more →ANNXAnnexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. has announced the grant of an inducement equity award to a new non-executive employee under the Nasdaq Listing Rule 5635(c)(4). The award consists of an option to purchase 20,000 shares at an exercise price of $5.66, which was the closing price of the stock on the grant date. The option has a ten-year term and will vest over four years. This move aligns with Annexon's dedication to advancing therapies for neuroinflammatory diseases.
Read more →ANNXAnnexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference
Annexon Biosciences will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026. CEO Douglas Love will discuss the company's innovative platform of targeted immunotherapies aimed at neuroinflammatory diseases. The event will be accessible via a live webcast and archived for 30 days. Annexon focuses on addressing serious conditions affecting millions globally.
Read more →About Annexon, Inc.
Headquarters1400 SIERRA POINT PARKWAY, BRISBANE, CA, 94005
Founded2011
BIOPHARMAWATCH ELITE PLUS
Trade the next ANNX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime